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Open access under CC BStimulation of iNKT cells by a-galactosyl ceramide (a-GalCer), also known as KRN7000, and its truncated
analogue OCH induces both Th1- and Th2-cytokines, with OCH inducing a Th2-cytokine bias. Skewing of
the iNKT cells’ response towards either a Th1- or Th2-cytokine proﬁle offers potential therapeutic bene-
ﬁts. The length of both the acyl and the sphingosine chains in a-galactosyl ceramides is known to inﬂu-
ence the cytokine release proﬁle. We have synthesized analogues of a-GalCer with truncated sphingosine
chains for biological evaluation, with particular emphasis on the Th1/Th2 distribution. Starting from a
common precursor, D-lyxose, the sphingosine derivatives were synthesised via a straightforward Wittig
condensation.
 2010 Elsevier Ltd. Open access under CC BY license.O
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The distinctive class of T cells, known as invariantNatural Killer T
(iNKT) cells, display characteristics of both T cells and NK cells and
play a crucial role indiverse immune responses andother pathologic
conditions.1 The synthetic glycolipid a-galactosyl ceramide
(a-GalCer),2 known as KRN7000 (1) (Fig. 1), is a powerful agonist,
which when presented by CD1d, activates iNKT cells to release
diverse cytokines, including both Th1- and Th2-cytokines.3 Once
stimulated, iNKT cells also activate other cells such as dendritic cells,
T cells and B cells.4 It is believed that the release of proinﬂammatory
Th1 cytokines such as interferon-c (INF-c)may contribute to antitu-
mour and antimicrobial functionswhile that of immunomodulatory
Th2-cytokines such as interleukin 4 (IL-4) may help alleviate auto-
immune diseases5 such as multiple sclerosis6 (MS) and arthritis.7
Maintaining the right balance between Th1- and Th2-cytokines is
of utmost importance as over activation of Th1 cells or suppression
of Th2 ones can lead to autoimmune diseases.8
Moreover, skewing of the cytokine release proﬁle towards a Th2
one can help in the treatment of autoimmune and inﬂammatory
conditions.9,10 For example, compound 5, commonly referred to
as OCH (Fig. 1), has been shown to protect mice against experimen-
tal encephalomyelitis (an animal model for MS) by favouring the
release of the Th2-cytokine IL-4 and suppressing the myelin
antigen-speciﬁc Th1 responses.6,11Y license.Crystal structures of bothmouse12 andhumanCD1d13 have iden-
tiﬁed the antigen-binding site as consisting of two channels or pock-
ets; A0 and F0, linedwith hydrophobic residues.While the A0 channel
can accommodate an alkyl chain consisting of up to 26 carbons (the
acyl chain in a-GalCer), the F0 channel can accommodate an alkyl
chain of 18 carbons (the sphingosine chain ina-GalCer).13,14 The sta-
bility of the bound glycolipid/CD1d complex and in turn the binding
afﬁnity of the latter to T cell receptors (TCR) are believed to largely
inﬂuence the immunological response.6,14 The apparent skewing to-
wards a Th2 response in the case of OCH (5) is allegedly due to a less
stable bound CD1d complex resulting in a less prolonged TCR stim-
ulation.6,14,15 a-Galactosyl ceramides with variations in the acyl
chain have been extensively studied, andhave also exhibited similar
effects on the cytokine release proﬁle.9 However, the properties of
analogues ofa-GalCerwith variations in the sphingosine chain, such
as OCH (5) have yet to be fully explored.2 n = 5
3 n = 8
4 n = 11
Figure 1. CD1d agonist KRN7000, OCH, and analogues.
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invaluable tools in understanding the functioning of CD1d and
NKT cells in a wide range of immune responses. Speciﬁcally,
compounds such as OCH (5), that are able to alter the polarisation
of Th1 or Th2, have potential therapeutic values for certain dis-
eases. As such, we have synthesised compounds 2, 3 and 4
(Fig. 1), with varying phytosphingosine chain lengths consisting
of 9–15 carbons, to investigate their effect on the Th1/Th2 balance
as well as to study their overall biological properties.
2. Results and discussion
Various methods, including dihydroxylation reactions16 and
Sharpless asymmetric epoxidation17 have been described in the lit-
erature for the synthesis of sphingolipids.18 Yet, the preparation of
such compounds remains nontrivial. In contrast to many reported
syntheses, the strategy employed by Lin et al.19 is quite concise and
affords a relatively high yield of the ﬁnal phytosphingosine from
the readily available D-lyxose. Their method is particularly attrac-
tive as D-lyxose already possesses the required stereogenic centres
and an SN2 displacement of a suitable leaving group at C-4 allows
the introduction of the amine functionality in the molecule. It is
noteworthy that Plettenburg et al.20 also used a similar strategy,
involving conversion of their substrate to phytosphingosine via a
Wittig condensation, in their reported synthesis.
Wehave therefore adapted both thesemethods to synthesise our
analogous sphingosines. We ﬁrst embarked on the synthesis of the
appropriate phosphonium salts required for the chain extending
Wittig oleﬁnation reaction. Thiswas easily achieved by reﬂuxing tri-
phenylphoshine with the corresponding alkyl halides in toluene
overnight. For the C-9, C-12, and C-15 phytosphingosine chain
lengths, 1-iodobutane, 1-bromooctane and 1-bromodecane were
used, respectively. Once isolated, they were resuspended in THF
and treatedwith n-BuLi at78 C to generate theWittig ylids, as de-
scribed by Plettenburg et al.20 Subsequently, the protected lyxose
derivative 6, which was synthesised as previously described,19 was
condensed with the ylids to afford the desired oleﬁns 7, 8 and 9 as
a mixture of cis and trans isomers (Scheme 1). In their preparation
of the C-18 phytosphingosine, Lin et al.19 proceeded to the reductionOH
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Scheme 1. Reagents: (a) n-BuLi, THF, phosphonium salts (C4H9PPh3+I,
C7H15PPh3+Br, C10H21PPh3+Br; (b) MsCl, pyridine, CH2Cl2, quant; (c) HCl, MeOH/
CH2Cl2; (d) H2, Pd–BaSO4, THF; (e) NaN3, DMF.of thedouble bondafter theWittig condensation via catalytic hydro-
genation using palladium hydroxide (Pd(OH)2). However, in our
hands, after several attempts the hydrogenation failed to go to com-
pletion after prolonged reaction periods. In an attempt to drive the
reaction to completion, the catalyst was ﬁltered off and replaced
with fresh one. Although the reaction was eventually completed
after 48 h, the trityl protecting groupwas also cleaved, thereby leav-
ing the primary alcohol unprotected. An alternative strategy where
the protecting groups would be removed prior to hydrogenation of
the double bondwas therefore envisaged. Hence, the remaining free
secondary hydroxyl group was mesylated by reaction with meth-
anesulfonyl chloride in dichloromethane. Themesyl group acts both
as a temporaryprotectinggroupanda good leaving group for the fol-
lowing inversion of stereochemistry at this position. Removal of the
trityl and acetonide protecting groups by acid treatment then
yielded compounds 13, 14 and 15 in quantitative yields. The reduc-
tion of the double bond by hydrogenation, catalysed by 5% palla-
dium on barium sulphate proceeded smoothly to give compounds
16, 17 and 18. We substituted the Pd(OH)2 with palladium on bar-
ium sulphate because the latter is less active and is more suitable
for use in the presence of the mesylate group. Finally, the amine
functional group was introduced into the molecule by an SN2 dis-
placement of the mesylate with sodium azide in DMF. Sphingosine
analogues 19, 20 and 21 were thus obtained in reasonable yields
for further use as glycosyl acceptors.
Hence, following the standard conditions described previ-
ously21 and summarised in Scheme 2, the sphingosine acceptors
22–24 were synthesized. Consistent with our previous work, ben-
zoate esters, rather than benzyl ethers, were adopted as protecting
groups to circumvent the hydrogenolysis reaction.
With respect to the glycosyl donor, we have previously success-
fully employed the bulky 4, 6-O-di-tert-butylsilylene (DTBS) group
as a-directing in galactosylation donors.22 DTBS ensures the exclu-
sive formation of an a-glycosidic linkage, irrespective of the nature
of the acceptor, and remains the protecting group of choice in chal-
lenging glycosylation reactions. However with our glycosyl accep-
tors, we were inclined to adopt Gervay-Hague’s rather simpliﬁed
glycosylation strategy employing glycosyl iodides and promoted
by tetrabutyl ammonium iodide (TBAI).23 Indeed, the latter’s group
recently reported both excellent stereoselectivity and yields for the
synthesis of a-GalCer and other similar compounds.24,25 It is
hypothesised that the a-selectivity is due to the TBAI-catalysed
isomerization of the a-glycosyliodide to the b-anomer.26 This
strategy represents a straightforward approach to the synthesis
of our target compounds given that the donor can be easily ob-
tained in large quantities in contrast to the multi-step preparation
of other galactosyl donors. The per-O-tetramethylsilyl-a-D-galacto-
pyranosyl iodide 25 was therefore generated by the reaction of the
per-O-pentamethylsilyl-a-D-galactose with 1 equiv of iodotrimeth-
ylsilane26 and then added to the respective phytosphingosine
acceptors 22–24 which were premixed with diisopropylethyl-HO
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Figure 2. CIR-hCD1d cells were pulsed with GSL and used to stimulate iNKT cells.
Supernatant was assayed for IL-4 (A) and IFN-c (B) by ELISA.
Figure 3. A (upper and lower pannel) IL4/IFNc and IFNc/IL4 ratio (human iNKT
cells), B (upper and lower pannel) IL4/IFNc and IFNc/IL4 ratio (mice iNKT cells); two
mice per group were injected with 1 lg of lipid ip and sera was assayed at 2 h (IL4)
or 24 h (IFNc) by ELISA.
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temperature, the solvent was evaporated and the TMS protecting
groups were removed by treatment with an acidic resin in MeOH.
The glycosylated compounds 26–28 were obtained as the a-ano-
mer exclusively in good overall yields of over 60%. The formation
of the desired a-linkage in compounds 26–28 was conﬁrmed by
the H-1 and C-1 signals in 1H and 13C NMR, respectively. Finally,
Zemplen’s deprotection of the benzoate protecting groups, fol-
lowed by hydrogenation of the azido group in methanol provided
the amines which were acylated with the fully saturated fatty acid,
hexacosanoic acid. This was accomplished by reaction of the corre-
sponding acid chloride with the free amine in a 1:1 mixture of THF
and saturated sodium acetate solution. Glycosphingolipds (GSL) 2
(OCH9), 3 (OCH12) and 4 (OCH15) were obtained as white solids
after concentration of the organic phase and puriﬁcation of the res-
idue by ﬂash chromatography.
To evaluate the biological activity of compounds OCH9 (2),
OCH12 (3) and OCH15 (4), human B cells expressing CD1d (C1R
CD1d) were pulsed with different concentrations of lipids and
incubatedwith a human iNKT cell line. iNKT cell activation (as deter-
mined by both IL-4 and IFN-c secretion in the culture supernatant)
elicited by OCH15 (4) was comparable to that obtained with
a-GalCer 1 (Fig. 2). On the other hand, compounds OCH9 (2) and
OCH12 (3) were found to be weaker stimulants of iNKT cells as less
IL-4 and IFN-c were observed. These data clearly indicate that the
iNKT cells’ activation by the GSLs OCH9 (2), OCH12 (3) and OCH15
(4) correlate with the length of their sphingosine chains, with the
longest chain inducing the greatest cytokine response.However, un-
like what was previously observed with mouse iNKT cells,27 the
cytokine proﬁle of human iNKT cells stimulated by OCH9 (2) and
OCH12 (3) was not as strongly biased towards a Th2 response
(Fig. 2A).14 Increasing amounts of IFN-cwere observedwith increas-
ing concentrations of OCH9 (2) and OCH12 (3), as opposed to what
was observed with mouse iNKT cells (Fig. 3).27
We previously performed kinetic and afﬁnity experiments to
investigate the effect of the phytosphingosine chain length on
the stability of the bound glycolipid/CD1d complex and on TCRbinding afﬁnity.14 We reported that shortening the phytosphingo-
sine chain increased the rate of dissociation of the GSLs from
hCD1d molecules and led to a decrease of the binding afﬁnity of
the iNKT TCR for hCD1d–GSL complexes.14 The increase in the Kd
value as the phytosphingosine chain got shorter was attributed
to both a decrease in kon and an increase in koff. Furthermore, our
results indicated an important role of the phytosphingosine chain
in controlling the formation of the immunological synapse and
iNKT cell activation.14
As a control, a-GalCer, OCH9, OCH12 and OCH15 were com-
pared with C20:2 (Fig. 4), a compound known to induce a Th2
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Figure 4. Analogue of a-GalCer inducing a Th2 skewing.
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was observed between a-GalCer and the various GSLs with human
iNKT cells (Fig. 3A, upper panel), a net increase was observed with
mice iNKT cells (Fig. 3B, upper pannel). In mice C20:2 and the trun-
cated GSLs OCH9, OCH12 and OCH15 favour the release of the Th2-
cytokine IL4. Similarly, the IFNc/IL4 ratio observed with a-GalCer
with mice iNKT cells (Fig. 3B, lower pannel) demonstrates that
the latter favours the release of the Th1 cytokine IFNc, conﬁrming
that in mice, compounds C20:2, OCH9, OCH12 and OCH15 induce
varying extents of Th2 skewing.
3. Conclusions
In conclusion we have developed a synthetic strategy for the
successful syntheses of three truncated analogues of a-GalCer,
adapted from examples present in the literature. ELISA assays of
these compounds with hCD1d and human iNKT cells showed dif-
ferent results than those observed with mice iNKT cells. The trun-
cated analogues OCH9 (2), OCH12 (3) and OCH15 (4) were found to
be generally less potent than a-GalCer (1). Also there was no Th2
skewing observed in this present study with the shorter phyto-
sphingosine chain lengths. Furthermore, control comparison
experiments showed that GSLs OCH9 (2), OCH12 (3), OCH15 (4)
and C20:2 cause a Th2 skewing in mice iNKT cells, thereby con-
ﬁrming the viability of our assays.
4. Experimental
1H NMR spectra were recorded at 400 MHz or 300 MHz, using
Bruker AMX 400, Bruker AV 400, Bruker AV 300 and Bruker AC
300 spectrometers. 13C NMR spectra were recorded at 100 MHz
or 75 MHz, respectively, using Bruker AMX 400, Bruker AV 400,
Bruker AV 300 and Bruker AC 300 spectrometers. Chemical shifts
are reported as d values (ppm) referenced to the following solvent
signals: CHCl3, dH 7.26; CDCl3, dC 77.0; CH3OH, dH 3.34; CD3OD, dC
49.9. Quaternary carbons were reported only when observed. Opti-
cal rotations were measured at 23 C and reported in
degdm1 g1 cm3. HRMS were recorded on a Micromass LCT spec-
trometer using a lock mass incorporated into the mobile phase. All
reagents were obtained from commercial sources, and were used
without further puriﬁcation unless stated otherwise. Anhydrous
solvents were purchased from Sigma–Aldrich, UK, stored over 4 Å
molecular sieves and under an Ar atmosphere. Analytical thin layer
chromatography (TLC) was performed on aluminium plates pre-
coated with Merck silica gel 60A F-254 as adsorbent. The devel-
oped plates were air dried, visualised by UV detection (at
254 nm) and/or stained with 5% phosphomolybdic acid in EtOH
(MPA spray). Compounds were puriﬁed by ﬂash column chroma-
tography on Merck silica gel (particle size 40–63 lm mesh) or Fluka
60 (40–60 lm mesh) silica gel.
4.1. Generalprocedure for the synthesis of phosphonium salts (a)
A mixture of triphenyl phosphine (3 equiv) and the alkyl halide,
1-iodobutane, 1-bromoheptane and 1-bromodecane, respectively,
(1 equiv) in toluene was reﬂuxed overnight. The mixture was thenallowed to cool and then ﬁltered. The precipitate was washed with
cold toluene and dried under vacuo to give the phosphonium salts
which were used in the next step without further puriﬁcation.4.2. General procedure for the synthesis of Wittig salts (ylids)
and subsequent oleﬁnation (b)
The phosphonium salt was resuspended in THF and cooled
to 10 C. nBuLi (2.5 M solution in hexanes, 2.8 equiv) was added
dropwise and the reaction mixture was stirred for 30 min, before
a solution of 6 (1 equiv) in dry THF was added. The resulting solu-
tion was stirred overnight at room temperature. Upon completion
of the reaction, the reaction was quenched with MeOH, followed by
80% MeOH in H2O, and the mixture was extracted with heptane
(4  20 mL). The combined organic layers were then washed with
brine (30 mL), dried over anhydrous Na2SO4 and concentrated in
vacuo. The residue was puriﬁed by puriﬁed by ﬂash chromatogra-
phy using hexanes/EtOAc (10:1) to give the desired products.4.3. (2R,3S,4R,5E/Z)-3,4-O-Isopropylidene-1-O-trityloxy-non-5-
en-2-ol 7
Prepared following general procedures (a) and (b) using triphen-
ylphosphine (18.36 g, 70.0 mmol) and iodobutane (4.29 g,
23.3 mmol), n-BuLi (26.8 mL, 65.2 mmol) and 6 (10.10 g,
23.3 mmol) to afford compound 7 as a white solid in 82% yield as a
mixture of cis and trans isomer in a 1:2.3 ratio (9.03 g, 19.1 mmol).
1H NMR (CDCl3): d 7.19–7.49 (15H, m, Ar–H), 5.53–5.57 (2H, m,
H-5, H-6), 4.90–4.94 (0.7 H, m, H-4trans), 4.45 (0.3H, dd,
J4,5 = J3,4 = 7.4 Hz, H-4cis), 4.28–4.30 (0.3H, m, H-3cis), 4.22–4.25
(0.7H, m, H-3trans), 3.77–3.81 (0.7H, m, H-2trans), 3.69–3.73 (0.3H,
m, H-2cis), 3.25 (0.3H, dd, J1a,2 = 5.1, J1a,1b = 9.5 Hz, H-1acis),
3.18–3.20 (0.7H, m, H-1atrans), 3.07–3.15 (1H, m, H-1btrans, H-1bcis),
1.75–2.06 (2H, m, H-7acis, H7bcis, H-7atrans, H-7btrans), 1.58, 1.52,
1.39, 1.37 (6H, 4s, 4  C(CH3)2), 1.22–1.32 (2H, m, CH2), 0.87 (3H, t,
J = 7.3 Hz, CH3); 13C NMR (75 MHz, CDCl3): d 144.1 (O2C(CH3)2),
135.8 (C-5), 127.3, 128.0 (CAr), 125.5 (C-6), 79.5 (C-2), 73.3 (C-3),
69.4 (C-4), 65.2 (C-1), 30.6, 30.1 (C-7, C-8), 28.5, 25.7 (2  C(CH3)3),
14.9 (C-9); HRMS calcd for C31H36O4 [M+Na]+: 495.2511, found
495.2511.4.4. (2R,3S,4R,5E/Z)-3,4-O-Isopropylidene-1-O-trityloxy-dodec-
5-en-2-ol 8
Prepared following general procedures (a) and (b) using tri-
phenylphosphine (18.00 g, 68.7 mmol) and 1-bromoheptane
(12.24 g, 22.9 mmol), n-BuLi (26.4 mL, 64.2 mmol) and 6 (9.90 g,
22.9 mmol) to afford compound 8 as a colourless syrup in 63% yield
as a mixture of cis and trans isomer in a 1:2.3 ratio (5.88 g,
13.68 mmol). 1H NMR (CDCl3): d 7.19–7.48 (15H, m, Ar–H),
5.47–5.58 (2H, m, H-5, H-6), 4.91–4.93 (0.7 H, m, H-4trans),
4.43–4.46 (0.3H, m, H-4cis), 4.25 (0.3H, dd, J2,3 = J3,4 = 4.6 Hz,
H-3cis), 4.21 (0.7H, dd, J2,3 = J3,4 = 4.4 Hz, H-3trans), 3.68–3.81
(0.7H, m, H-2trans), 3.51–3.56 (0.3H, m, H-2cis), 3.22 (0.3H, dd,
J1a,2 = 5.1, J1a,1b = 5.3 Hz, H-1acis), 3.18 (0.7H, dd, J1a,2 = 9.5,
J1a,1b = 5.3 Hz, H-1atrans), 3.07–3.17 (1H, m, H-1btrans, H-1bcis),
1.91–2.09 (2H, m, H-7acis, H7bcis, H-7atrans, H-7btrans), 1.54, 1.49,
1.39, 1.38 (6H, 4s, 4  C(CH3)2), 1.19–1.39 (8H, m, CH2), 0.88 (3H,
t, J = 5.7 Hz, CH3); 13C NMR (75 MHz, CDCl3): d 145.9,
(O2C(CH3)2), 137.3 (C-5), 129.1, 129.9, 130.8 (CAr), 127.1 (C-6),
79.5 (C-2), 75.1 (C-3), 71.3 (C-4), 67.1 (C-1), 34.2, 31.3, 31.1, 29.7,
25.0 (C-7–C-12), 29.8, 27.1 (2  C(CH3)3), 17.1 (C-12); HRMS calcd
for C34H42O4 [M+Na]+: 537.2980, found 537.2982.
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pentadec-5-en-2-ol 9
Prepared following general procedures (a) and (b) using triphen-
ylphosphine (54. 6 g, 0.20 mol, 3 equiv) and 1-bromodecane (15.4 g,
69.5 mmol), n-BuLi (74.0 mL, 0.18 mol) and 6 (10.00 g, 23.2 mmol)
to afford compound 9 as a colourless syrup in 55% yield as amixture
of cis and trans isomer in a 1:2.3 ratio (7.12 g, 12.8 mmol). 1H NMR
(CDCl3): d 7.19–7.48 (15H, m, Ar–H), 5.47–5.58 (2H, m, H-5, H-6),
4.91–4.93 (0.7 H, m, H-4trans), 4.40–4.46 (0.3H, m, H-4cis), 4.25
(0.3H, dd, J2,3 = J3,4 = 4.6 Hz, H-3cis), 4.21 (0.7H, dd, J2,3 = J3,4 =
4.4 Hz, H-3trans), 3.72–3.79 (0.7H, m, H-2trans), 3.68–3.70 (0.3H, m,
H-2cis), 3.22 (0.3H, dd, J1a,2 = 5.1, J1a,1b = 5.3 Hz, H-1acis), 3.15 (0.7H,
dd, J1a,2 = 9.5, J1a,1b = 5.3 Hz, H-1atrans), 3.08–3.13 (1H, m, H-1btrans,
H-1bcis), 1.71–2.03 (2H, m, H-7acis, H7bcis, H-7atrans, H-7btrans),
1.56, 1.47, 1.39, 1.38 (6H, 4s, 4  C(CH3)2), 1.11–1.35 (14H, m,
CH2), 0.87 (3H, t, J = 6.7 Hz, CH3); 13C NMR (75 MHz, CDCl3):
d 145.7, (O2C(CH3)2), 137.2 (C-5), 130.6, 129.7, 128.9 (CAr), 126.8
(C-6), 79.5 (C-2), 74.9 (C-3), 70.8 (C-4), 66.5 (C-1), 34.0, 31.3, 31.2,
30.0 (C-7–C-14), 29.9, 27.0 (2  C(CH3)3), 16.0 (C-15); HRMS calcd
for C37H48O4 [M+Na]+: 579.3450, found 579.3454.
4.6. General procedure for mesylation reaction (c)
Compounds 7, 8 and 9 (1 equiv) were, respectively, dissolved in
a mixture of anhydrous CH2Cl2 and dry pyridine (3:1) and cooled to
0 C. Methanesulfonylchloride (1.6 equiv) was then added drop-
wise and the reaction mixture stirred for 4 h at room temperature.
Upon completion of the reaction, the reaction was quenched with
sodium bicarbonate solution, diluted with CH2Cl2 (20 mL) and
washed successively with water (20 mL) and brine (20 mL). The or-
ganic layer was dried over anhydrous Na2SO4 and evaporated un-
der vacuo to give the mesylated compounds 10, 11 and 12 as
thick syrups in quantitative yields.
4.7. (2R,3S,R,5E/Z)-3,4-O-Isopropylidene-2-methanesulfonyl-
oxy-1-O-trityloxy-non-5-enol 10
Prepared following general procedure (c) using 7 (6.46 g,
13.7 mmol) and methanesulfonyl chloride (1.8 mL, 22.7 mmol) in
a mixture of CH2Cl2 (45 mL) and pyridine (20 mL) to afford com-
pound 10 (6.13 g, 11.2 mmol) as an off-white solid in 82% yield
as a mixture of cis and trans isomer in a 1:2.3 ratio. 1H NMR
(CDCl3): d 7.21–7.49 (15H, m, Ar–H), 5.89–5.48 (2H, m, H-5, H-6),
4.78–5.07 (1H, m, H-2), 4.34–4.50 (2H, m, H-3, H-4), 3.92–4.26
(2H, m, H-1a, H-1b), 3.14, 3.12 (3H, 2s, OSO2CH3), 1.85–2.12 (2H,
m, H-7acis, H7bcis, H-7atrans, H-7btrans), 1.58, 1.52, 1.39, 1.37 (6H,
4s, 4  C(CH3)2), 1.22–1.31 (2H, m, CH2), 0.85 (3H, t, J = 7.2 Hz,
CH3); 13C NMR (75 MHz, CDCl3): d 141.4 (O2C(CH3)2), 135.3
(C-5), 126.9, 126.8, 126.1 (CAr), 121.9 (C-6), 79.2 (C-2), 74.3 (C-3),
70.2 (C-4), 61.3 (C-1), 37.2 (COSO2CH3), 34.6, 28.7 (C-7, C-8),
28.5, 25.7 (2  C(CH3)3), 14.9 (C-9); HRMS calcd for C32H38SO6
[M+Na]+: 573.2287, found 573.2290.
4.8. (2R,3S,4R,5E/Z)-3,4-O-Isopropylidene-2-
methanesulfonyloxy-1-O-trityloxy-dodec-5-enol 11
Prepared following general procedure (c) using 8 (2.59 g,
5.0 mmol) and methanesulfonyl chloride (0.62 mL, 8.06 mmol) in
amixture of CH2Cl2 (25 mL) andpyridine (8 mL) to afford compound
11 (2.80 g, 4.7 mmol) as a colourless oil in 94% yield as a mixture of
cis and trans isomer in a 1:2.3 ratio. 1H NMR (CDCl3): d 7.17–7.52
(15H, m, Ar–H), 5.03–5.52 (2H, m, H-5, H-6), 4.79–4.82 (1H, m,
H-2), 4.58–4.75 (2H, m, H-3, H-4), 4.48 (0.7H, dd, J1a,2 = 5.9,
J1a,1b = 8.4 Hz, H-1atrans), 4.24 (0.3H, dd, J1a,2 = 6.9, J1a,1b = 14.0 Hz,
H-1acis), 3.54–3.57 (0.3H, m, H-1btrans), 3.45 (0.7H, dd, H-1bcis),2.99, 3.18 (3H, 2s, OSO2CH3), 1.57–1.82 (2H, m, H-7acis, H7bcis,
H-7atrans, H-7btrans), 1.48, 1.41, 1.39, 1.38 (6H, 4s, 4  C(CH3)2),
1.10–1.33 (8H, m, CH2), 0.85 (3H, t, J = 6.7 Hz, CH3); 13C NMR
(75 MHz, CDCl3): d 144.8 (O2C(CH3)2), 137.8 (C-5), 130.2, 129.4,
128.7 (CAr), 125.1 (C-6), 82.5 (C-2), 77.6 (C-3), 73.7 (C-4), 64.6
(C-1), 39.9 (COSO2CH3), 35.1, 30.9, 30.2 (C-7, C-8, C-9), 29.5, 28.1
(2  C(CH3)3), 29.0 (C-10), 24.5 (C-11), 16.8 (C-9); HRMS calcd for
C35H44SO6 [M+Na]+: 615.2757, found 615.2560.
4.9. (2R,3S,4R,5E/Z)-3,4-O-Isopropylidene-2-
methanesulfonyloxy-1-O-trityloxy-pentadec-5-enol 12
Prepared following general procedure (c) using 9 (5.39 g,
9.67 mmol) and methanesulfonyl chloride (1.3 mL, 16.1 mmol) in
a mixture of CH2Cl2 (45 mL) and pyridine (15 mL) to afford
compound 12 (5.52 g, 8.70 mmol) as an opaque oil in 90% yield as
a mixture of cis and trans isomer in a 1:2.3 ratio. 1H NMR (CDCl3):
d 7.19–7.48 (15H, m, Ar–H), 5.40–5.48 (0.7H, m, H-6trans),
5.28–5.37 (0.7H, m, H-5trans), 5.20–5.25 (0.3H, m, H-6cis),
4.97–5.06 (0.3H, M, H-5cis), 4.79–4.85 (0.7H, m, H-2trans), 4.72–
4.75 (0.7H, m, H-4trans), 4.62–4.66 (0.3H, m, H-2cis), 4.57–
4.61(0.3H, m, H-4cis), 4.49 (0.7H, dd, J3,4 = 8.7, J2,3 = 5.6 Hz, H-3trans),
4.20 (0.3H, dd, J3,4 = 9.4, J3,2 = 4.2 Hz, H-3cis), 3.45–3.56 (2H,m, H-1a,
H-1b), 3.04, 3.10 (3H, 2s,OSO2CH3), 1.85–2.12 (2H,m,H-7acis, H7bcis,
H-7atrans, H-7btrans), 1.59–1.82 (2H, m, H-7), 1.48, 1.47, 1.38, 1.36
(6H, 4s, 4  C(CH3)2), 1.08–1.32 (14H, m, CH2), 0.88 (3H, t,
J = 6.5 Hz, CH3); 13C NMR (75 MHz, CDCl3): d 144.3 (O2C(CH3)2),
137.3 (C-5), 129.7, 128.9, 128.2 (CAr), 124.6 (C-6), 82.0 (C-2), 77.1
(C-3), 73.2 (C-4), 64.1 (C-1), 40.1 (COSO2CH3), 33.1, 32.4, 30.5,
30.3, 30.2 (C-7, C-14), 26.8, 26.6 (2  C(CH3)3), 16.9 (C-15); HRMS
calcd for C38H50SO6 [M+Na]+: 657.3226, found 657.3223.
4.10. General procedure for deprotection and reduction of
double bond (d)
The mesylated compounds 10, 11 and 12 were, respectively,
dissolved in a mixture of dry CH2Cl2 and MeOH (2:1) (20 mL) and
concentrated hydrochloric acid (3 mL) was added dropwise and
the mixture stirred at room temperature for 2 h, after which time
TLC analysis indicated that the reactionwas complete. Solid sodium
bicarbonate was then added to quench the reaction until the
solution was neutral. The mixture was then ﬁltered and the ﬁltrate
concentrated. The residue was dissolved again in EtOAc and the or-
ganic solution washed consecutively with water (2  20 mL), brine
(20 mL), dried over anhydrous Na2SO4 and concentrated in vacuo.
The residues were puriﬁed by ﬂash chromatography (gradient from
to hexanes/EtOAc (4:1) to neat EtOAc) and dissolved in THF (10 mL).
Fivepercentageof Pd–Ba(SO4)2 (0.1 equiv)was added to the solution
and the mixture was stirred under H2 overnight, after which time it
was ﬁltered through a pad of Celite, which was subsequently
washed with CHCl3/MeOH (1:1). The combined ﬁltrates were
concentrated to yield compounds 13, 14 and 15.
4.11. (2R,3S,4R)-2-Methanesulfonyloxy-nonane-1,3,4-triol 16
Prepared following general procedure (d) using 10 (5.06 g,
9.18 mmol) to give 16 as an off-white wax (1.91 g, 7.07 mmol) in
77% yield. 23[a]D = 80.0 (c 1.00, CH3OH). 1H NMR (CD3OD): d
4.84–4.88 (1H, m, H-2), 3.78–3.88 (2H, m, H1a, H-1b), 3.49–3.55
(1H, m, H-4), 3.43–3.47 (1H, dd, J2,3 = 8.3, J3,4 = 2.2 Hz, H-3), 3.15
(3H, s, OSO2CH3), 2.76 (3H, br s, OH), 1.67–1.75 (1H, m, H-5a),
1.46–1.53 (1H, m, H-7a), 1.19–1.38 (6H, m, H-5b, H-6a, H-6b, H-
8a, H-8b), 0.88 (3H, t, J = 6.8 Hz, CH3); 13C NMR (75 MHz, CD3OD):
d 82.9 (C-2), 73.6 (C-3), 70.5 (C-4), 62.3 (C-1), 38.4 (COSO2CH3),
33.1, 32.0, 25.2, 22.8 (C-5–C-8), 14.0 (C-9); HRMS calcd for
C10H22SO6 [M+Na]+: 293.1035, found 293.1026.
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Prepared following general procedure (d) using 11 (2.46 g,
4.15 mmol) to give 17 as a colourless syrup (0.946 g, 3.03 mmol)
in 73% yield. 23[a]D = 32.2 (c 1.00, CH3OH). 1H NMR (CD3OD): d
4.74–4.78 (1H, m, H-2), 3.62–3.78 (2H, m, H1a, H-1b), 3.31–3.47
(1H, m, H-4), 3.18–3.21 (1H, m, H-3), 3.06 (3H, s, OSO2CH3),
1.48–1.56 (2H, m, H-5a, H-7a), 1.22–1.43 (12H, m, CH2), 0.73
(3H, t, J = 6.5 Hz, CH3); 13C NMR (75 MHz, CD3OD): d 83.9 (C-2),
74.7 (C-3), 71.5 (C-4), 63.3 (C-1), 40.1 (COSO2CH3), 34.2, 33.1,
30.9, 30.8 30.5, 26.5, 23.8 (C-5–C-11), 15.1 (C-12); HRMS calcd
for C13H28SO6 [M+Na]+: 335.1504, found 335.1511.4.13. (2R,3S,4R)-2-Methanesulfonyloxy-pentadecane-1,3,4-triol
18
Prepared following general procedure (d) using 12 (6.93 g,
10.9 mmol) to give 18 as a white solid (2.79 g, 7.87 mmol) in
72% yield. 23[a]D = 180.0 (c 1.00, CH3OH). 1H NMR (CD3OD):
d 4.99–5.05 (1H, m, H-2), 3.98–4.04 (2H, m, H1a, H-1b), 3.55–3.62
(1H, m, H-4), 3.45–3.49 (1H, m, H-3), 3.15 (3H, s, OSO2CH3),
1.48–1.86 (2H, m, H-5a, H-7a), 1.22–1.43 (18H, m, CH2), 0.89 (3H,
t, J = 6.8 Hz, CH3); 13C NMR (75 MHz, CD3OD): d 85.4 (C-2), 75.6 (C-
3), 72.8 (C-4), 64.1 (C-1), 40.1 (COSO2CH3), 34.3, 33.1, 32.0, 30.8,
30.4, 29.2, 28.7, 26.2, 25.2, 22.8 (C-5–C-14), 16.2 (C-15); HRMS calcd
for C16H34SO6 [M+Na]+: 377.1974, found 377.1980.4.14. General procedure for displacement of mesylate group
with sodium azide (e)
The mesylated compounds were dissolved in DMF (10 mL) and
sodium azide (2 equiv) was added. The reaction was stirred over-
night at 60 C, after which, it was taken up in water (50 mL) and
extracted with EtOAc (3  15 mL). The combined organic layers
were then washed with brine (30 mL), dried over anhydrous
Na2SO4 and evaporated. The residue was then puriﬁed by ﬂash
chromatography using hexanes/EtOAc (4:1).4.15. (2S,3S,4R)-2-Azido-nonane-1,3,4-triol 19
Prepared following general procedure (e) using 16 (0.74 g,
2.75 mmol), sodiumazide (0.36 g, 5.50 mmol) to afford awhite solid
(0.38 g, 1.73 mmol, 63%). 23[a]D = +144.0 (c 1.00, CH3OH). 1H NMR
(CD3OD): d 3.82–3.86 (1H, dd, J1a,1b = 11.5, J1a,2 = 4.9 Hz, H-1a),
3.71–3.77 (1H, m, H-1b), 3.58–3.64 (2H, m, H-3, H-4), 3.44–3.47
(1H, ddd, J1b,2 = 9.9, J2,3 = 4.5 Hz), 1.45–1.56 (2H, m, H-5a, H-7a),
1.38 (1H, m, H-5b), 1.27–1.14 (5H, m, CH2), 0.79 (3H, t, J = 6.1 Hz,
CH3); 13C NMR (75 MHz, CD3OD): d 74.0 (C-3), 71.9 (C-4), 62.7
(C-2), 61.0 (C-1), 31.5 (C-5), 31.3 (C-6), 24.9 (C-7), 22.1 (C-8), 13.5
(C-9); HRMS calcd for C9H19N3O3[M+Na]+: 240.1324, found
240.1315.
4.16. (2S,3S,4R)-2-Azido-dodecane-1,3,4-triol 20
Prepared following general procedure (e) using 17 (0.95 g,
3.03 mmol), sodium azide (0.39 g, 6.06 mmol) to afford a colour-
less syrup (0.69 g, 2.64 mmol, 87%). 23[a]D = +45.0 (c 1.00, CH3OH).
1H NMR (CD3OD): d 3.88–3.95 (1H, dd, J1a,1b = 11.1, J1a,2 = 3.3 Hz,
H-1a), 3.71–3.80 (1H, m, H-1b), 3.54–3.63 (1H, m, H-4),
3.48–3.53 (1H, m, H-3), 3.28–3.32 (1H, m, H-2), 1.20–1.45 (11H,
m, CH2), 0.89 (3H, t, J = 6.2 Hz, CH3); 13C NMR (75 MHz, CD3OD):
d 75.9 (C-3), 72.8 (C-4), 66.2 (C-2), 62.4 (C-1), 33.8, 32.9, 30.7,
30.3, 26.6, 23.6 (C-5–C-11), 13.8 (C-12); HRMS calcd for
C12H25N3O3[M+Na]+: 282.1794, found 282.1794.4.17. (2S,3S,4R)-2-Azido-pentadecane-1,3,4-triol 21
Prepared following general procedure (e) using 18 (2.64 g,
7.45 mmol), sodium azide (0.97 g, 14.91 mmol) to afford a colour-
less oil (1.61 g, 5.36 mmol, 72%).23[a]D = +31.4 (c 1.00, CH3OH). 1H
NMR (CD3OD): d 3.92–3.98 (1H, dd, J1a,1b = 11.4, J1a,2 = 3.3 Hz,
H-1a), 3.74–3.88 (1H, m, H-1b), 3.58–3.66 (1H, m, H-4),
3.41–3.58 (1H, m, H-3), 3.32–3.36 (1H, m, H-2), 1.51–1.76(3H, m,
CH2), 1.18–1.47 (17H, m, CH2), 0.91 (3H, t, J = 6.6 Hz, CH3); 13C
NMR (75 MHz, CD3OD): d 73.9 (C-3), 70.8 (C-4), 64.6 (C-2), 60.4
(C-1), 31.8, 31.0, 28.7, 28.4, 24.7, 21.7 (C-5–C-14), 13.6 (C-15);
HRMS calcd for C12H25N3O3[M+Na]+: 324.2263, found 324.2275.
4.18. Preparation of glycosyl acceptors 22, 23 and 24
Compounds 19, 20 and 21 were subjected to the same standard
reaction conditions described by Akimoto et al.21 and depicted in
Scheme 2 for the preparation of (2R, 3S, 4R)-2-azido-3, 4-di-O-(ben-
zoyloxy)-octadecan-1-ol.
4.19. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-nonan-1-ol 22
23[a]D = +81.4 (c 1.00, CHCl3). 1H NMR (CDCl3): d 7.48–8.07
(10H, m, Ar–H), 5.49–5.46 (2H, m, H-3, H-4), 3.98–4.01 (1H, m,
H-1a), 3.75–3.82 (2H, m, H-1b, H-2), 1.82–1.99 (2H, m, H-5a,
H-5b), 1.18–1.51 (6H, m, CH2), 0.89 (3H, t, J = 6.8 Hz, CH3); 13C
NMR (75 MHz, CDCl3): d 166.1, 165.7 (C@O), 133.7–129.7 (CAr),
129.3, 129.1, 128.6, 128.4 (CAr), 73.4 (C-3), 72.9 (C-4), 63.1 (C-2),
62.1 (C-1), 31.5 (C-7), 29.7 (C-5), 25.2 (C-6), 22.4 (C-8), 13.9
(C-9); HRMS calcd for C23H27N3O5[M+Na]+: 448.1848, found
448.1829.
4.20. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-dodecan-1-ol 23
23[a]D = +8.8 (c 1.00, CHCl3). 1H NMR (CDCl3): d 7.26–7.89 (10H,
m, Ar–H), 5.32–5.39 (2H, m, H-3, H-4), 3.65–3.82 (1H, m, H-1a),
3.54–3.60 (2H, m, H-1b, H-2), 1.62–1.82 (2H, m, H-5a, H-5b),
1.06–1.30 (12H, m, CH2), 0.68 (3H, t, J = 6.7 Hz, CH3); 13C NMR
(75 MHz, CDCl3): d 136.4.7–131.1 (CAr), 76.1 (C-3), 75.4 (C-4),
66.2 (C-2), 64.8 (C-1), 34.5, 33.0, 30.7, 30.3, 26.6, 23.6 25.3
(C-5–C11), 16.7 (C-12); HRMS calcd for C26H33N3O5[M+Na]+:
490.2318, found 490.2316.
4.21. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-pentadecan-1-ol
24
23[a]D = +157.2 (c 1.00, CHCl3). 1H NMR (CDCl3): d 7.25–8.11
(10H, m, Ar–H), 5.48–5.5.4 (2H, m, H-3, H-4), 4.82 (1H, dd,
J1a,2 = 7.3, J1a,1b = 14.6 Hz, H-1a), 3.67–4.03 (2H, m, H-1b, H-2),
177–1.97 (2H, m, H-5a, H-5b), 1.09–1.46 (18H, m, CH2), 0.85 (3H,
t, J = 6.6 Hz, CH3); 13C NMR (75 MHz, CDCl3): d 162.5 (C@O),
135.8–130.6 (CAr), 75.4 (C-3), 75.1 (C-4), 65.3 (C-2), 64.3 (C-1),
34.0, 32.6, 32.4, 31.5, 29.7, 25.2, 23.8, 23.2, 22.8 22.4 (C-5–C14),
16.2 (C-15); HRMS calcd for C29H39N3O5[M+Na]+: 532.6370, found
532.6373.
4.22. General procedure for glycosylation reaction (f)
To a solution of the persilylated galactose (3 equiv) in anhy-
drous CH2Cl2 (20 mL), iodotrimethylsilane (3 equiv) was added
and the reaction mixture stirred at room temperature under argon
for 30 min. The mixture was then concentrated and azeotroped
twice with dry benzene (5 mL). The yellow residue was dissolved
in dry benzene and kept under argon. Meanwhile, activated 4 Å
molecular sieves, tetrabutyl ammonium iodide (6 equiv), respec-
tive glycosyl acceptors 22, 23 and 24 (1 equiv) and diisopropyleth-
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condenser. Benzene (10 mL) was added and the solution stirred at
70 C for 20 min. The solution of the glycosyl iodide 25 in benzene
was then cannulated into the two-necked ﬂask and stirred at room
temperature for two days. Upon completion of the reaction, the
mixture was ﬁltered through Celite and the Celite pad was washed
with CH2Cl2 (10 mL). The ﬁltrate was washed with saturated so-
dium thiosulfate (10 mL), brine (10 mL), dried over anhydrous
Na2SO4 and concentrated in vacuo. The residue was dissolved in
MeOH and Dowex 50WX8-200 ion exchange resin was added
and the mixture stirred at room temperature overnight. The latter
was then ﬁltered and the ﬁltrate concentrated to give a residue
which was puriﬁed by ﬂash chromatography using EtOAc/hexanes
(7:1) to give the glycosylated product.
4.23. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-1-(a-D-galacto-
pyranosyl)-nonane 26
Prepared following general procedure (f) using per-O-pentam-
ethylsilyl-a-D-galactose (0.27 g, 0.49 mmol), iodotrimethylsilane
(0.09 g, 0.07 mL, 0.49 mmol), TBAI (3.65 mg, 0.99 mmol), DIPEA
(97.5 mg, 0.13 mL, 0.74 mmol) and 22 (70 mg, 0.16 mmol) to afford
26 as a pale yellow oil (43 mg, 0.07 mmol) in 46% yield.
23[a]D = +36.1 (c 1.00, CHCl3). 1H NMR (CDCl3): d7.38–7.96 (10H,
m, Ar–H), 5.59–5.61 (1H, m, H-3Cer), 5.40–5.50 (1H, m, H-4Cer),
4.80 (1H, s, H-1), 4.10–4.13 (1H, dd, J6a, 6b = 7.9, J5,6a = 3.0 Hz,
H-6a), 3.91–3.94 (2H, m, H-2Cer, H-4), 3.80–3.84 (1H, dd,
J2,3 = J3,4 = 6.0 Hz,H-3), 3.70–3.75 (4H,m,H-2,H-5,H-1aCer, H-1bCer),
3.62–3.67 (1H, m, H-6b), 1.81–1.91 (2H, m, H-5aCer, H-5bCer),
1.15–1.41 (6H, m, CH2), 0.83 (3H, t, J = 6.4 Hz, CH3); 13C NMR
(75 MHz, CDCl3): d 167.1, 167.0 (C@O), 127.4–133.4 (CAr), 101.4
(C-1), 73.2 (C-4Cer), 72.1 (C-3Cer), 70.9 (C-3), 70.6 (C-5), 70.2 (C-4),
69.7 (C-2), 68.1 (C-6), 62.4 (C-1Cer), 61.0 (C-2Cer), 21.9–33.3
(4  CH2Cer), 13.9 (CH3Cer); HRMS calcd for C29H37N3O10[M+Na]+:
610.6183, found 610.6188.
4.24. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-1-(a-D-galacto-
pyranosyl)-dodecane 27
Prepared following general procedure (f) using per-O-pentam-
ethylsilyl-a-D-galactose (0.85 g, 1.58 mmol), iodotrimethylsilane
(0.32 g, 0.23 mL, 1.58 mmol), TBAI (1.17 g, 3.16 mmol), DIPEA
(1.05 g, 1.42 mL, 8.16 mmol) and 23 (0.25 g, 0.53 mmol) to afford
27 as an off-white solid (110 mg, 0.17 mmol) in 33% yield..
23[a]D = +92.4 (c 1.00, CHCl3). 1H NMR (CDCl3): d7.38–7.98 (10H,
m, Ar–H), 5.61–5.64 (1H, m, H-3Cer), 5.48–5.52 (1H, m, H-4Cer),
4.79 (1H, s, H-1), 4.11–4.13 (1H, dd, J6a, 6b = 8.0, J5.6a = 2.9 Hz,
H-6a), 3.90–3.93 (2H, m, H-2Cer, H-4), 3.82–3.85 (1H, m, H-3),
3.71–3.75 (4H, m, H-2, H-5, H-1aCer, H-1bCer), 3.63–3.67 (1H, dd,
J5,6b = 6.0 Hz, H-6b), 1.81–1.94 (2H, m, H-5aCer, H-5bCer), 1.18–1.42
(12H,m, CH2), 0.79 (3H, t, J = 6.7 Hz, CH3); 13CNMR (75 MHz, CDCl3):
d 166.8, 166.3 (C@O), 128.7–134.2 (CAr), 100.2 (C-1), 73.7 (C-4Cer),
72.6 (C-3Cer), 71.4 (C-3), 70.6 (C-5), 70.2 (C-4), 69.5 (C-2), 67.9
(C-6), 62.1 (C-1Cer), 61.2 (C-2Cer), 22.9–32.1 (6  CH2Cer), 14.2
(CH3Cer); HRMS calcd for C32H43N3O10[M+Na]+: 652.2846, found
610.2845.
4.25. (2S,3S,4R)-2-Azido-3,4-di-O-(benzoyloxy)-1-(a-D-galacto-
pyranosyl)-pentadecane 28
Prepared following general procedure (f) using per-O-pentam-
ethylsilyl-a-D-galactose (1.61 g, 2.97 mmol), iodotrimethylsilane
(0.59 g, 0.43 mL, 2.97 mmol), TBAI (2.19 g, 5.94 mmol), DIPEA
(0.58 g, 0.78 mL, 4.45 mmol) and 24 (0.50 g, 0.99 mmol) to afford
28 as an off-white solid (175 mg, 0.26 mmol) in 26% yield..
23[a]D = +81.4 (c 1.00, CHCl3). 1H NMR (CDCl3): d7.37–8.02 (10H,m, Ar–H), 5.62–5.66 (1H, m, H-3Cer), 5.48–5.55 (1H, m, H-4Cer),
4.80 (1H, d, J1,2 = 2.4 Hz H-1), 4.12–4.16 (1H, m, H-6a), 3.90–3.95
(2H, m, H-2Cer, H-4), 3.83–3.85 (1H, m, H-3), 3.71–3.74 (4H, m,
H-2, H-5, H-1aCer, H-1bCer), 3.63–3.69 (1H, m, H-6b), 1.82–1.92
(2H, m, H-5aCer, H-5bCer), 1.15–1.30 (16H, m, CH2), 0.82 (3H, t,
J = 6.9 Hz, CH3); 13C NMR (75 MHz, CDCl3): d 135.1–139.5 (CAr),
106.5 (C-1), 79.5 (C-4Cer), 78.1 (C-3Cer), 71.4 (C-3), 70.8 (C-5),
70.0 (C-4), 69.5 (C-2), 67.7 (C-6), 63.4 (C-1Cer), 62.6 (C-2Cer),
22.9–36.8 (11  CH2Cer), 19.5 (CH3Cer); HRMS calcd for
C35H49N3O10[M+Na]+: 694.7686, found 694.7683.
4.26. General procedure for the removal of benzoate esters,
hydrogenation of the azido group and subsequent N-acylation
(g)
Compounds 26, 27 and 28were, respectively, dissolved inMeOH
and a 1 M solution of NaOMe (5 mL) was added. The mixture was
stirred at room temperature for 2 h, after which time TLC analysis
indicated that the reaction was complete. The reaction was neutra-
lisedby theadditionofDowex50WX8-200 resin. The latterwas then
ﬁltered and the ﬁltrate concentrated to give a residue which was
puriﬁed by ﬂash chromatography using EtOAc/MeOH (7:1) to give
compounds 29, 30 and 31 in quantitative yields. Compounds 29,
30 and 31 were, respectively, dissolved in MeOH (10 mL) and
stirred with Pd–C (5 mg) under H2 overnight, after which time the
mixture was ﬁltered through a pad of Celite, which was subse-
quently washed with MeOH. The combined ﬁltrates were concen-
trated to give the respective amines as white solids. The crude
aminewas then dissolved in a 1:1mixture of THF/NaOAC (saturated
solution) (5 mL) and the freshly prepared acid chloride of hexacosa-
noic acid was added. The reaction was allowed to stir vigorously
overnight at room temperature after which the organic phase was
removed. The aqueous phase was further extracted with THF
(2  1 mL), and the combined organic phases were concentrated.
The residue was ﬁnally puriﬁed by ﬂash chromatography (gradient
from CHCl3 to 15% MeOH in CHCl3) to give target compounds 2, 3
and 4.
4.27. (2S,3S,4R)-1-(a-D-Galactopyranosyl)-2-hexacosanoylami-
no-3,4-nonanediol 2
Prepared following general procedure (g) using 26 (50 mg,
0.12 mmol) and hexacosanoic acid (71 mg, 0.18 mmol, 1.5 equiv)
to give 2 as a white solid (31 mg, 0.04 mmol) in 35% yield..
23[a]D = +12.6 (c 1.00, CHCl3/CH3OH 2:1). 1H NMR (CDCl3/CD3OD
2:1): d 4.85 (1H, d, J1,2 = 3.4 Hz, H-1), 4.13–4.16 (1H, m, H-2Cer),
3.86–3.89 (1H,m, H-3), 3.81–3.86 (1H, dd, J1a,2 = 4.6, J1a,1b = 10.5 Hz,
H-1aCer), 3.72–3.78 (2H, m, H-2, H-5), 3.66–3.72 (3H, m, H-4, H-6a,
H-6b), 3.60–3.66 (1H, m, H-1bCer), 3.47–3.55 (2H, m, H-3Cer,
H-4Cer), 2.13–2.18 (2H, m, NHCOCH2C24H49), 1.53–1.67 (3H, m,
CH2), 0.94–1.46 (49H, m, CH2), 0.79 (6H, t, J = 6.7 Hz, CH3); 13C
NMR (75 MHz, (CDCl3/CD3OD 2:1)): d 103.6 (C-1), 77.7 (C-3Cer),
75.4 (C-4Cer), 73.7 (C-5), 73.2 (C-4), 72.6 (C-3), 71.7 (C-2), 70.7
(C-1Cer), 65.2 (C-6), 64.7 (C-2Cer), 23.8–33.4 (CH2), 15.9 (CH3, CH3Cer);
HRMS calcd for C41H81NO9 [M+Na]+: 754.5809, found 754.5812.
4.28. (2S,3S,4R)-1-(a-D-Galactopyranosyl)-2-hexacosanoylami-
no-3,4-dodecanediol 3
Prepared following general procedure (g) using 27 (100 mg,
0.16 mmol) and hexacosanoic acid (95 mg, 0.24 mmol, 1.5 equiv)
to give 3 as a white solid (45 mg, 0.06 mmol) in 37% yield.
23[a]D = +15.6 (c 1.00, CHCl3/CH3OH 2:1). 1H NMR (CDCl3/CD3OD
2:1): d 4.85 (1H, d, J1,2 = 3.8 Hz, H-1), 4.12–4.16 (1H, m, H-2Cer),
3.87–3.89 (1H, m, H-3), 3.81–3.85 (1H, dd, J1a,2 = 4.8,
J1a,1b = 10.5 Hz, H-1aCer), 3.72–3.77 (2H, m, H-2, H-5), 3.66–3.72
228 N. Veerapen et al. / Bioorg. Med. Chem. 19 (2011) 221–228(3H, m, H-4, H-6a, H-6b), 3.61–3.66 (1H, m, H-1bCer), 3.47–3.51
(2H, m, H-3Cer, H-4Cer), 2.14–2.18 (2H, m, NHCOCH2C24H49), 1.46–
1.65 (3H, m, CH2), 1.16–1.34 (57H, m, CH2), 0.82 (6H, t, J = 6.6 Hz,
CH3); 13C NMR (75 MHz, (CDCl3/CD3OD 2:1)): d 101.8 (C-1), 76.9
(C-3Cer), 74.2 (C-4Cer), 73.2 (C-5), 73.0 (C-4), 72.6 (C-3), 71.8 (C-
2), 70.1 (C-1Cer), 65.5 (C-6), 64.4 (C-2Cer), 24.8–36.0 (CH2), 17.0
(CH3, CH3Cer); HRMS calcd for C44H87NO9 [M+Na]+: 797.6289,
found 797.6291.
4.29. (2S,3S,4R)-1-(a-D-Galactopyranosyl)-2-hexacosanoylami-
no-3,4-pentadecanediol 4
Prepared following general procedure (g) using 28 (100 mg,
0.15 mmol) and hexacosanoic acid (90 mg, 0.22 mmol, 1.5 equiv)
to give 4 as a white solid (44 mg, 0.05 mmol) in 36% yield.
23[a]D = +26.7 (c 1.00, CHCl3/CH3OH 2:1). 1H NMR (CDCl3/CD3OD
2:1): d 4.85 (1H, d, J1,2 = 3.7 Hz, H-1), 4.13–4.16 (1H, m, H-2Cer),
3.87–3.89 (1H,m, H-3), 3.81–3.86 (1H, dd, J1a,2 = 4.8, J1a,1b = 11.0 Hz,
H-1aCer), 3.72–3.77 (2H, m, H-2, H-5), 3.66–3.71 (3H, m, H-4, H-6a,
H-6b), 3.61–3.66 (1H, m, H-1bCer), 3.46–3.51 (2H, m, H-3Cer,
H-4Cer), 2.13–2.18 (2H, m, NHCOCH2C24H49), 1.46–1.65 (3H, m,
CH2), 1.11–1.35 (70H, m, CH2), 0.83 (6H, t, J = 6.8 Hz, CH3); 13C
NMR (75 MHz, (CDCl3/CD3OD 2:1)): d 102.5 (C-1), 76.8 (C-3Cer),
74.9 (C-4Cer), 73.7 (C-5), 73.1 (C-4), 72.9 (C-3), 71.9 (C-2), 70.7
(C-1Cer), 65.0 (C-6), 64.5 (C-2Cer), 25.6–35.1 (CH2), 16.9 (CH3, CH3Cer);
HRMS calcd for C50H99NO9 [M+Na]+: 838.6760, found 838.6755.4.30. Elisa
C1R-hCD1d cells were pulsed for overnight with GSLs. 5  104
cell-pulsed targets were incubated at 37 C with 2  104 iNKT cells
in a ﬁnal volume of 200 lL. After 36 h, the supernatants were har-
vested, and the concentrations of IFN-c and IL-4 were determined
by commercial ELISA (BD Pharmingen).Acknowledgments
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